Considerations for the management of urgency symptoms in patients with overactive bladder syndrome

World Journal of Urology

Volumn 27, Issue 6, 2009, Pages 755-763

  Cardozo, Linda D ^a,b   Van Kerrebroeck, Philip E V A ^c   Staskin, David R ^d  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b University Hospital ^*  (United Kingdom)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Incontinence; Pharmacotherapy; Urgency

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; HUMAN; OVERACTIVE BLADDER; PATHOPHYSIOLOGY; URGE INCONTINENCE;

HUMANS; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, URGE;

EID: 71249136785     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0455-4     Document Type: Article

References (62)

1. P Abrams 2005 Urgency: the key to defining the overactive bladder BJU Int 96 Suppl 1 1 3 10.1111/j.1464-410X.2005.05648.x (Pubitemid 41224300)
2. MJ Hung E Ho P-S Shen M-J Sun A Lin G-D Chen 2006 Urgency is the core symptom of female overactive bladder syndrome as demonstrated by statistical analysis J Urol 176 636 640 10.1016/j.juro.2006.03.062 (Pubitemid 43927928)
3. Y Homma 2008 Lower urinary tract symptomatology: its definition and confusion Int J Urol 15 35 43
4. MMK Donaldson JR Thompson RJ Matthews HM Dallosso CW McGrother 2006 The natural history of overactive bladder and stress urinary incontinence in older women in the community: a 3 year prospective cohort study Neurourol Urodyn 25 709 716 10.1002/nau.20235 (Pubitemid 44691371)
5. LA Møller G Lose T Jørgensen 2000 Incidence and remission rates of lower urinary tract symptoms at one year in women aged 40-60: longitudinal study Br Med J 320 1429 1432 10.1136/bmj.320.7247.1429
6. Wennberg A, Molander U, Fall M, Edlund E, Peeker R, Milsom I (2009) A Longitudinal population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in women. Eur Urol doi: 10.1016/j.eururo.2009.01.007
7. P Abrams JG Blaivas S Stanton JT Andersen 1988 ICS standardisation of terminology of lower urinary tract function Neurourol Urodyn 7 403 426 10.1002/nau.1930070502 (Pubitemid 18275631)
8. P Abrams L Cardozo M Fall D Griffiths P Rosier U Ulmstein P van Kerrebroeck A Victor A Wein 2002 The standardisation of terminology of lower urinary tract function: report from the standardisation sub committee of the international continence society Neurourol Urodyn 21 167 178 10.1002/nau.10052 (Pubitemid 34195211)
9. CK Payne C Kelleher 2007 Redefining response in overactive bladder syndrome BJU Int 99 101 106 10.1111/j.1464-410X.2007.06517.x (Pubitemid 44915628)
10. Cardozo L, Dewilde T, Feyereisl J, Wadie B, Amarenco G, Liapis A, Drogendijk T, Wright M, Bolodeoku J (2006) Solifenacin significantly reduces both urgency severity and bother: results from the flexible dose, placebo controlled, multinational SUNRISE study. Neurol Urodyn 25(6) (abstract 281)
11. Serels S, Andoh M, Smith N (2006) Solifenacin significantly improves urgency in overactive bladder (OAB) patients compared to placebo. Urology 68 (Suppl 5a):72 MP-04.11
12. A Nixon S Colman L Sabounjian B Sandage U Schwiderski D Staskin N Zinner 2005 A validated patient reported measure of urinary urgency severity in overactive bladder for use in clinical trials J Urol 174 604 607 10.1097/01.ju.0000165461.38088.7b (Pubitemid 40981612)
13. Rudy D, Cline K, Goldberg K, Harris R (2004) A multicenter, randomized, placebo controlled trial of trospium chloride in overactive bladder patients. ICS and IUGA (Paris, France) (abstract 144)
14. N Zinner M Harnett L Sabounjian B Sandage R Dmochowski D Staskin 2005 The overactive bladder-symptom composite score: a composite symptom score of toilet voids, urgency severity and urge urinary incontinence in patients with overactive bladder J Urol 173 1639 1643 10.1097/01.ju.0000154692.73129.d8 (Pubitemid 40524794)
15. Andersson K-E, Appell R, Cardozo L, Chapple C, Drutz H, Fourcroy J, Nishizawa O, Vela Navarette R, Wein A (2005) In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Third international consultation in incontinence, Monaco, 26-29 June 2005, Chap 14. Health Publications Ltd.
16. http://www.urotoday.com/287/conference-coverage/ici-2008/2757/
17. National Institute for Health and Clinical Excellence (2006) Urinary incontinence: the management of urinary incontinence in women, vol 40. NICE Clinical Guideline. http://www.nice.org.uk/CG040
18. C Chapple V Khullar Z Gabriel JA Dooley 2005 The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis Eur Urol 48 5 26 10.1016/j.eururo.2005.02.024 (Pubitemid 40835585)
19. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 4:CD003781
20. V Khullar C Chapple Z Gabriel JA Dooley 2006 The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis Urology 68 Suppl 2 38 48 10.1016/j.urology.2006.05.043 (Pubitemid 44189489)
21. Alhasso AA, McKinlay J, Patrick K, Stewart L (2008) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2:CD003193
22. C Chapple V Khullar Z Gabriel D Muston CE Bitoun D Weinstein 2008 The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol 54 3 543 562 10.1016/j.eururo.2008. 06.047
23. C Song JT Park KO Heo KS Lee M-S Choo 2006 Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study J Korean Med Sci 21 1060 1063 10.3346/jkms.2006. 21.6.1060
24. A Mattiasson J Blaakaer K Høye AJ Wein 2003 Tolterodine Scandanavian Study Group. Simplified bladder training augments the effectiveness of tolterodine in patients with an overactive bladder BJU Int 91 1 54 60 10.1046/j.1464-410X.2003.03076.x (Pubitemid 36098796)
25. Burgio KL, Kraus SR, Menefee S, Borello-France D, Corton M, Johnson HW, Mallett V, Norton P, FitzGerald MP, Dandreo KJ, Richter HE, Rozanski T, Albo M, Zyczynski HM, Lemack GE, Chai TC, Khandwala S, Baker J, Brubaker L, Stoddard AM, Goode PS, Nielsen-Omeis B, Nager CW, Kenton K, Tennstedt SL, Kusek JW, Debuene Chang T, Nyberg LM, Steers W for the Urinary Incontinence Treatment Network. Behavioral therapy to enable women with urge incontinence to discontinue drug treatment. Ann Intern Med 2008;149(3):161-169
26. MB Chancellor F Kianifard E Beamer L Mongay U Ebinger G Hicks 2008 DelConte: a comparison of the efficacy of darifenacin alone vs. darifenacin plus a behavioural modification programme upon the symptoms of overactive bladder Int J Clin Pract 62 4 606 613 10.1111/j.1742-1241.2008.01714.x (Pubitemid 351348040)
27. P Herbison J Hay-Smith G Ellis K Moore 2003 Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review BMJ 326 841 844 10.1136/bmj.326.7394.841
28. AR Morris JI Westbrook KH Moore 2008 A longitudinal study over 5 to 10 years of clinical outcomes in women with idiopathic detrusor overactivity BJOG 115 239 246 10.1111/j.1471-0528.2007.01527.x (Pubitemid 350233603)
29. LD Cardozo E Heβdörfer R Milani P Arañó L Dewilde M Slack T Drogendijk M Wright J Bolodeoku 2008 Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomised, double-blind, placebo-controlled, rising-dose trial BJU Int 102 9 1120 1127 10.1111/j.1464-410X.2008.07939.x
30. Karram MM, Toglia MR, Serels SR, Andoh M, Fakhoury A, Forero-Schwanhaeuser S (2009) Treatment with solifenacin increases warning time and improves symptoms of overactive bladder. Results from VENUS, a randomized, double-blind, placebo-controlled trial. Urology 73 (1):14-8 (Epub 2008 Nov 8)
31. Serels S, Andoh M, Smith N (2006) Solifenacin treatment in patients with OAB reduces symptom bother and improves health-related quality of life. Urology 68 (suppl 5a):73 MP-04.15
32. Cardozo L, Nagy G, Kiss L, Al-Shukri S, Mikulas J, Svihra J, Drogendijk T, Wright M, Bolodeoku J (2006) Solifenacin in the treatment of urgency symptoms of overactive bladder in a flexible dose, placebo controlled trial (the SUNRISE study). Int Urogyn J 17(Supp 2) (abstract 052)
33. N Zinner L Noe L Rasouliyan T Marshall R Seifeldin 2008 Impact of solifenacin on resource utilization, work productivity and health utility in overactive bladder patients switching from tolterodine ER Curr Med Res Opin 24 6 1583 1591 10.1185/03007990802081766 (Pubitemid 351929057)
34. 3 selective receptor antagonist, is an effective and well tolerated once daily treatment for overactive bladder Eur Urol 45 420 429 10.1016/j.eururo.2004.01.008 (Pubitemid 38376197)
35. 3 SRA), compared with oxybutinin in the treatment of patients with overactive bladder World J Urol 23 248 252 10.1007/s00345-005-0507-3
36. V Khullar ES Rovner R Dmochowski V Nitti J Wang Z Guan 2008 Fesoterodine dose response in subjects with overactive bladder syndrome Urology 71 5 839 843 10.1016/j.urology.2007.12.017 (Epub 17 Mar 2008)
37. Chapple CR, Rechberger T, Al-Shukri A, Meffan P, Everaert K, Huang M, Ridder A on behalf of the YM-905 study group (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solofenacin in patients with symptomatic overactive bladder. BJU Int 93:303-310 (Pubitemid 38253574)
38. CR Chapple R Martinez-Garcia L Selvaggi P Toozs-Hobson W Warnack T Drogendijk DM Wright J Bolodeoku 2005 A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial Eur Urol 48 464 470
39. L Cardozo M Lisec R Millard O van Vierssen Trip I Kuzmin TE Drogendijk M Huang AM Ridder 2004 Randomized, double-blind placebo controlled trial of the once daily antimuscarinic agent solifenacin succinate in patients with overactive bladder J Urol 172 1919 1924 10.1097/01.ju.0000140729.07840.16 (Pubitemid 39363090)
40. N Zinner A Mattiason S Stanton 2002 Efficacy, safety and tolerability of extended release once daily tolterodine treatment for overactive in older versus younger patients JAGS 50 5 709 807 10.1046/j.1532-5415.2002.50203.x (Pubitemid 34496674)
41. RR Dmochowski PK Sand NR Zinner DR Staskin 2008 Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study Urology 71 449 454 10.1016/j.urology.2007.11.008
42. M Halaska G Ralph A Wiedemann G Primus B Ballering-Bruhl K Höfner, et al. 2003 Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability World J Urol 20 6 392 399 (Epub 2003 Mar 28)
43. D Staskin P Sand N Zinner 2007 Dmochowski for the trospium study group. Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial J Urol 178 978 984 10.1016/j.juro.2007.05.058 (Pubitemid 47211090)
44. H Madersbacher M Halaska R Voigt S Alloussi K Hofner 1999 A placebo-controlled, multicentre study comparing the tolerability and efficacy of propiverine and oxybutinin in patients with urgency and urge incontinence BJU Int 84 646 651 10.1046/j.1464-410x.1999.00251.x (Pubitemid 29457181)
45. MC Michel JJ de la Rosette 2005 Role of muscarinic receptor antagonists in urgency and nocturia BJU Int 96 Suppl 1 37 42 10.1111/j.1464-410X.2005.05651. x (Pubitemid 41224306)
46. N Zinner J Susset M Gittelman M Arguinzoniz L Rekeda F Haab 2006 Efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist an investigation of warning time in patients with OAB Int J Clin Pract 60 1 119 126 10.1111/j.1368-5031.2005.00770.x (Pubitemid 43732588)
47. L Cardozo A Dixon 2005 Increased warning time with darifenacin: a new concept in the management of urinary urgency J Urol 173 1214 1218 10.1097/01.ju.0000155798.78911.5 (Pubitemid 40380539)
48. LL Subak E Whitcomb H Shen J Saxton E Vittinghoff JS Brown 2005 Weight loss: a novel and effective treatment for urinary incontinence J Urol 174 1 190 195 10.1097/01.ju.0000162056.30326.83 (Pubitemid 40825712)
49. A Wang S Chih M Chen 2006 Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial Urology 68 5 999 1004 10.1016/j.urology.2006.05.038 (Pubitemid 44750132)
50. Majumdar (Personal communication) Inpatient bladder retraining (IBR): an evaluation of services in a tertiary referral centre (Majumdar A, Toozs-Hobson P, Parsons M, Hassan I, Robb K)
51. Wilson PD, Berghmans B, Hagen S, Hay-Smith J, Moore K, Nygaard I, Sinclair L, Yamanishi T, Wyman J, Dorey G (2005) In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Third international consultation in incontinence, Monaco, 26-29 June 2005, Chap 15. Health Publications Ltd.
52. KL Burgio PS Goode JL Locher MG Umlauf DL Roth HE Richter RE Varner LK Lloyd 2002 Behavioral training with and without biofeedback in the treatment of urge incontinence in older women JAMA 288 10 2293 2299 10.1001/jama.288.18.2293 (Pubitemid 35291759)
53. B Roe J Milne J Ostaszkiewicz S Wallace 2007 Systematic reviews of bladder training and voiding programmes in adults: a synopsis of findings on theory and methods using metastudy techniques J Adv Nurs 57 1 3 14 10.1111/j.1365-2648.2006.04098.x (Pubitemid 44973837)
54. PS Eriksen H Rasmussen 1992 Low-dose 17 beta-estradiol vaginal tablets in the treatment of atrophic vaginitis: a double-blind placebo controlled study Eur J Obstet Gynecol Reprod Biol 44 137 144 10.1016/0028-2243(92)90059-81587379
55. LD Cardozo BG Wise CJ Benness 2001 Vaginal oestradiol for the treatment of lower urinary tract symptoms in postmenopausal women: a double-blind placebo-controlled study J Obstet Gynaecol 21 383 385 10.1080/01443610120059941 (Pubitemid 32735275)
56. JE Steinauer LE Waetjen E Vittinghoff LL Subak SB Hulley D Grady F Lin JS Brown 2005 Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol 106 940 945 (Pubitemid 41532898)
57. SL Hendrix BB Cochrane IE Nygaard VL Handa VM Barnabei C Iglesia A Aragaki MJ Naughton RB Wallace SG McNeeley 2005 Effects of estrogen with and without progestin on urinary incontinence JAMA 293 935 948 10.1001/jama.293.8. 935 (Pubitemid 40271125)
58. PM Braun C Seif C van der Horst K-P Junemann 2004 Neuromodulation-sacral, peripheral and central: current status, indications, results and new developments EAU Update Ser 2 187 194 10.1016/j.euus.2004.09.005 (Pubitemid 39618957)
59. DM Schmid P Sauermann M Werner B Schuessler N Blick M Muentener RT Strebel D Perucchini D Scheiner G Schaer H John A Reitz D Hauri B Schurch 2006 Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics J Urol 176 177 185 10.1016/S0022-5347(06)00590-8
60. B Schurch 2006 Botulinum toxin for the management of bladder dysfunction Drugs 66 1301 1318 10.2165/00003495-200666100-00001 (Pubitemid 44246615)
61. C Silva J Silva H Castro F Reis P Dinis A Avelino F Cruz 2007 Bladder sensory desensitization decreases urinary urgency BMC Urol 7 9 10.1186/1471-2490-7-9 (Pubitemid 47019834)
62. D Robinson K Anders L Cardozo J Bidmead A Dixon J Balmfoth J Rufford 2003 What do women want? Interpretation of the concept of cure J Pelvic Med Surg 9 6 273 277 10.1097/01.spv.0000095060.05452.3f (Pubitemid 38160721)